Tumor-secreted LOXL2 Activates Fibroblasts Through FAK Signaling

por Barker, Holly E., Bird, Demelza, Lang, Georgina, Erler, Janine T.
Publicado 2013

The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence

por Barker, Holly E., Paget, James T. E., Khan, Aadil A., Harrington, Kevin J.
Publicado en Nat Rev Cancer (2015)

LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis

por Cox, Thomas R., Bird, Demelza, Baker, Ann-Marie, Barker, Holly E., Ho, Melisa W-Y., Lang, Georgina, Erler, Janine T.
Publicado 2013

Deaf-1 regulates epithelial cell proliferation and side-branching in the mammary gland

por Barker, Holly E, Smyth, Gordon K, Wettenhall, James, Ward, Teresa A, Bath, Mary L, Lindeman, Geoffrey J, Visvader, Jane E
Publicado 2008

LOXL2-mediated matrix remodeling in metastasis and mammary gland involution

por Barker, Holly E., Chang, Joan, Cox, Thomas R, Lang, Georgina, Bird, Demelza, Nicolau, Monica, Evans, Holly R., Gartland, Alison, Erler, Janine T.
Publicado 2011

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei

por Dillon, Magnus T., Barker, Holly E., Pedersen, Malin, Hafsi, Hind, Bhide, Shreerang A., Newbold, Kate L., Nutting, Christopher M., McLaughlin, Martin, Harrington, Kevin J.
Publicado en Mol Cancer Ther (2016)

An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation

por Patel, Radhika, Barker, Holly E., Kyula, Joan, McLaughlin, Martin, Dillon, Magnus T., Schick, Ulrike, Hafsi, Hind, Thompson, Alan, Khoo, Vincent, Harrington, Kevin, Zaidi, Shane
Publicado en Radiother Oncol (2017)

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status

por Hafsi, Hind, Dillon, Magnus T., Barker, Holly E., Kyula, Joan N., Schick, Ulrike, Paget, James T., Smith, Henry G., Pedersen, Malin, McLaughlin, Martin, Harrington, Kevin J.
Publicado en Front Oncol (2018)

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

por McLaughlin, Martin, Barker, Holly E., Khan, Aadil A., Pedersen, Malin, Dillon, Magnus, Mansfield, David C., Patel, Radhika, Kyula, Joan N., Bhide, Shreerang A., Newbold, Kate L., Nutting, Christopher M., Harrington, Kevin J.
Publicado en BMC Cancer (2017)

3D functional genomics screens identify CREBBP as a targetable driver in aggressive triple-negative breast cancer

por Peck, Barrie, Bland, Philip, Mavrommati, Ioanna, Muirhead, Gareth, Cottom, Hannah, Wai, Patty T., Maguire, Sarah L., Barker, Holly E., Morrison, Eamonn, Kriplani, Divya, Yu, Lu, Gibson, Amy, Falgari, Giulia, Brennan, Keith, Farnie, Gillian, Buus, Richard, Marlow, Rebecca, Novo, Daniela, Knight, Eleanor, Guppy, Naomi, Kolarevic, Daniela, Susnjar, Snezana, Milijic, Natasa Medic, Naidoo, Kalnisha, Gazinska, Patrycja, Roxanis, Ioannis, Pancholi, Sunil, Martin, Lesley-Ann, Holgersen, Erle M, Cheang, Maggie C.U., Noor, Farzana, Postel-Vinay, Sophie, Quinn, Gerard, McDade, Simon, Krasny, Lukas, Huang, Paul, Daley, Frances, Wallberg, Fredrik, Choudhary, Jyoti S., Haider, Syed, Tutt, Andrew N., Natrajan, Rachael
Publicado en Cancer Res (2021)